Replies to post #386 on TetraLogic Pharmaceuticals Corp (TLOG)

[©PROPHETABLE]

Last or said mid 2016, but interm results could be posted at anytime...

SHAPE also showed improvement in pruritus (itch), a significant symptom associated with CTCL. Thirty-eight percent of patients demonstrated a clinically meaningful decrease in pruritus during the study as measured by a Visual Analog Scale. The drug was well tolerated by patients in the study. The 60 patient study is now fully enrolled, and the company expects that final results will be available in mid-2016.